Von Willebrand factor and acute type a aortic dissection——VAD study

Abstract

Acute Type A Aortic Dissection (ATAAD) is a kind of cardiovascular disease which seriously threatens human life and health. Surgical treatment is currently recognized as the standard treatment for ATAAD. It has the characteristics of rapid onset, long operation time, and worse post-operative prognosis than other routine cardiac surgeries. Preoperative biomarkers correlated with the outcome of ATAAD was rarely reported. Future research should be directed toward finding out some useful predictive biomarkers and assessing their potential treatment value, in the hope of improving the postoperative prognosis of ATAAD. Von Willebrand factor (vWF) is considered to be closely related to pathophysiological processes such as blood coagulation and vascular inflammation. Its deficiency or elevation may affect patients' blood coagulation condition and postoperative intravascular inflammation, thus affecting the occurrence of postoperative hemorrhagic complications. The purpose of this study is to investigate the effect of vWF on the early postoperative outcome of patients with ATAAD. Method and analysis: Patients with ATAAD who receive surgical treatment in our center from April 1, 2021 to April 1, 2022 will be prospectively included. According to the preoperative vWF measurement, enrolled patients will be divided into two groups: normal vWF (normal level of vWF: NL-vWF, reference value of 50–160%) group and abnormal vWF (Disrupted level of vWF: DL-vWF) group. The preoperative baseline data (including demographic characteristics, comobidities and malperfusion syndrome state, imaging examination, and laboratory examination), and surgical data will be documented. Primary and secondary endpoints events (described in part 2.4) will be assessed and recorded. We will use propensity score approach to account for baseline differences between DL-vWF group and NL-vWF group, and compare the early postoperative outcomes for a purpose of assessing the effect of vWF on the early postoperative outcomes of patients with ATAAD. Highlights